REQUIP XL
ROPINIROLE HYDROCHLORIDE
Approval overview REQUIP XL is listed in Drugs@FDA under application 022008 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient ROPINIROLE HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor GLAXOSMITHKLINE LLC Submission history Latest submission status date: 2021-07-12 00:00:00.
Structured Monograph
Clinical summary
Approval overview REQUIP XL is listed in Drugs@FDA under application 022008 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ROPINIROLE HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor GLAXOSMITHKLINE LLC Submission history Latest submission status date: 2021-07-12 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.